Trial reportAnnals of hematology2015
Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.
Trial report in Annals of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- Integrated Molecular Risk Stratification and Measurable Residual Disease-Guided Consolidation Improve Outcomes in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia.Cancer medicine · 2026Article
- Acute megakaryoblastic leukemia with myeloid sarcoma among a pediatric patient harbouring RBM15::MRTFA: a case report and literature review.BMC pediatrics · 2026Review
- Superior long-term survival with acceptable safety of ATG/G-CSF-based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS-AMKL.Frontiers in oncology · 2026Article
- Article
- Extramedullary Relapse ofInternational journal of molecular sciences · 2025Article
- The RBM39 degrader indisulam inhibits acute megakaryoblastic leukemia by altering the alternative splicing of ZMYND8.Cell & bioscience · 2025Article
- Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm.Virchows Archiv : an international journal of pathology · 2025Article
- Azacitidine as maintenance therapy in pediatricFrontiers in immunology · 2025Article
- The Impact of Interactive Video Games Training on the Quality of Life of Children Treated for Leukemia.Cancers · 2024Article
- Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.Bone marrow transplantation · 2024Article
- Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene.Journal of pediatric hematology/oncology · 2024Article
- Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults.Cancers · 2024Review
- UnderstandingCancers · 2023Article
- Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group.Pediatric blood & cancer · 2023Article
- Lineage switch in a pediatric patient with KMT2A-MLLT3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review.International journal of hematology · 2023Review
- t(1;7;22)(p13;q21;q13) is a novel 3-way variant of t(1;22)(p13;q13) neonatal acute megakaryoblastic leukemia: A case report.Molecular and clinical oncology · 2023Article
- Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia With Unusual Immunophenotype.Cureus · 2023Article
- Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatricFrontiers in oncology · 2023Article
- A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia.Molecular and clinical oncology · 2022Article
- Interactive Video Games as a Method to Increase Physical Activity Levels in Children Treated for Leukemia.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances in the treatment of children with acute megakaryoblastic leukemia (AMKL) using intensified treatment protocols, clear prognostic indicators, and treatment recommendations for this acute myeloid leukemia (AML) subgroup are yet to be defined. Here, we report the outcome of 97 pediatric patients with de novo AMKL (excluding Down syndrome [DS]) enrolled in the prospective multicenter studies AML-BFM 98 and AML-BFM 04 (1998-2014). AMKL occurred in 7.4 % of pediatric AML cases, at younger age (median 1.44 years) and with lower white blood cell count (mean 16.5 × 10(9)/L) as compared to other AML subgroups. With 60 ± 5 %, children with AMKL had a lower 5-year overall survival (5-year OS; vs. 68 ± 1 %, P log rank = 0.038). Yet, we achieved an improved 5-year OS in AML-BFM 04 compared to AML-BFM 98 (70 ± 6 % vs. 45 ± 8 %, P log rank = 0.041). Allogeneic hematopoietic stem cell transplantation in first remission did not provide a significant survival benefit (5-year OS 70 ± 11 % vs. 63 ± 6 %; P Mantel-Byar = 0.85). Cytogenetic data were available for n = 78 patients. AMKL patients with gain of chromosome 21 had a superior 5-year OS (80 ± 9 %, P log rank = 0.034), whereas translocation t(1;22)(p13;q13) was associated with an inferior 5-year event-free survival (38 ± 17 %, P log rank = 0.04). However, multivariate analysis showed that treatment response (bone marrow morphology on day 15 and 28) was the only independent prognostic marker (RR = 4.39; 95 % CI, 1.97-9.78). Interestingly, GATA1-mutations were detected in six patients (11 %) without previously known trisomy 21. Thus, AMKL (excluding DS) remains an AML subgroup with inferior outcome. Nevertheless, with intensive therapy regimens, a steep increase in the survival rates was achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.